Education:
Bachelor of Science in Pharmacy, Unviersity of Toronto
Doctor of Pharmacy Degree, Duquesne University, Pittsburgh, PA
Hospital Pharmacy Residency, Toronto General Hospital, University Health Network

Interests:
Acute Coronary Syndromes
Practice Patterns and Outcomes

Recent Publications/Abstracts:

Bucci C, Sinclair A, Geerts W, Fremes S. Efficacy and Safety of Low Molecular Weight Heparin Anticoagulation After Heart Valve Surgery. [Abstract] Can J Card 2008;24(Suppl SE).

Bucci C, Mamdani M, Juurlink D, Tu J. Dihydropyridine Calcium Channel Antagonists and Cardiovascular Outcomes in Elderly Patients: A Population-Based Study. Can J Card 2008;24(8):629-632.

Bucci C, Sinclair A, Tawfik S, Geerts W, Pahk M, Bartle B. Implementation and Evaluation of a Pharmacy-Based Heparin-Induced Thrombocytopenia Safety Improvement Initiative in Cardiac Surgery. [Abstract] CJHP 2007;60:(Suppl 1)S53.

Bucci C, Holbrook A, Bates S, Cyr M. Severe Thrombotic Reaction and Amputation Following Initiation of Celecoxib: A Case Report. [Abstract] Can J Clin Pharm 2006;13(2).

Bucci C, Oh P. Medication Utilization Rates After Acute Myocardial Infarction in a Cardiac Rehabilitation Population. [Abstract] CJHP 2006;59:(Suppl 1)S53.

Selected Publications:

de Denus S, Zakrzewski M, Barhdadi A, Leblanc MH, Racine N, Bélanger F, Carrier M, Ducharme A, Dubé MP, Turgeon J, White M. J Heart Lung Transplant. 2011;30:326-31.

de Denus S. Angiotensin-converting enzyme inhibitors pharmacogenomics: getting ready for prime-time. Pharmacogenomics 2010;11:1375-8.

Beaulieu M, de Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010;11:1573-1590.

de Denus S, Dubé MP. Genetic determinants of blood pressure reduction following potassium supplementation: and the candidates are…" J Hypertension 2010:668-670.

de Denus S, Zakrzewski-Jakubiak M, Dubé MP, Bélanger F, Ducharme A, Racine N, Whittom L, Lavoie J, Touyz R, Turgeon J, White M. Effects of AGTR1 A1166C gene polymorphism in heart failure patients treated with Candesartan. Ann Pharmacother 2008;42:925-932.

Gaffney SM, de Denus S, Olson K, Ripley T, Robinette B, Summers K, Spencer A. Key Articles and Guidelines in the Management of Hypertension: 2008 Update. Pharmacotherapy 2008;28:1041-58.

de Denus S, Tardif JC, White M, Bourassa MG, Racine N, Lévesque S, Ducharme A. Temporal Variations in Hematocrit in Patients with Left Ventricular Dysfunction : Relationship with Cause-Specific Mortality and Morbidity and Optimal Monitoring –

Further Insights from SOLVD. Can J Cardiol 2008: 24: 45-48.

Zakrzewski-Jakubiak M, de Denus, S, Dubé MP, Bélanger F, White M, Turgeon J. Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure. Br J Clin Pharmacol 2008;742:65:742-751.

White M, Lepage S, Lavoie J, de Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Duchame A, Rouleau JL, Touyz R. Effects of Combined Candesartan and ACE Inhibitors on BNP, Markers of Inflammation and Oxidative Stress, and Glucose Regulation in Patients with Symptomatic Heart Failure. J Card Fail. 2007;13(2):86-94.

de Denus S, Tardif, JC, White M, Bourassa M, Racine N, Lévesque S, Ducharme A. Quantification of the Risk and Predictors of Hyperkalemia in Patients With Left Ventricular Dysfunction: A Retrospective Analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J 2006;152:705-12.

de Denus S, White M, Tardif, JC, Bourassa M, Racine N, Lévesque S, Ducharme A. Temporal increases in subclinical levels of inflammation are associated with adverse clinical outcomes in patients with left ventricular dysfunction. J Card Fail. 2006;12(5):353-9.

de Denus S, Sanoski C, Carlsson J, Opolski G, Spinler SA. Rate control versus rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165(3):258-62.

Current Position:
Clinical Co-ordinator / DUE, Colchester East Hants Health Authority, Truro, Nova Scotia
Adjunct Professor, College of Pharmacy, Dalhousie University, Halifax, Nova Scotia.
Clinical practice area – ICU/CCU

Education:
Bachelor of Science in Pharmacy Dalhousie University, Halifax, Nova Scotia
Doctor of Pharmacy (PharmD) Idaho State University, Pocatello, Idaho

Research and Practice Interests:
Cardiology and Drug Utilization and Policy Change

Presentations:

Oct 2008
Pain Management in the Elderly. Atlantic Provinces Inter-Professional Pain Conference. Halifax, NS

May 2007
Warfarin verses ASA: Pick your Poison. Canadian Therapeutics Congress, Halifax NS

Oct 2006
Atrial Fibrillation: Rate versus Rhythm Control. Contemporary Issues in Cardiovascular Disease Conference. Halifax, NS

May 2006
CHARISMA Trial. Joint Therapeutics Congress, Toronto, ON

April/May 2006
AACT (Addressing Additional Cardiovascular Risk Factors) in Hypertension. Glengarry, Truro NS and Glasgow Square, New Glasgow, NS.

April/May 2006
NSAIDs and the Arthritis Patient. Ramada Inn, Halifax, NS and Heather Hotel, Stellarton, NS

Oct 2005
Lead with the Facts: Health Canada’s Position on Coxibs and NSAIDs – Where do we go from here? Maritime Fall Refresher Symposium, Halifax, NS and St John’s Nfld.

May 2005
COX-2 Inhibitors – Behind the Headlines. CSHP Nova Scotia Branch AGM, Halifax, Nova Scotia

June 2003
Improving Cardiovascular Outcomes in Nova Scotia (ICONS) – Acute Coronary Syndrome Management. Cambridge Suites, Sydney, Nova Scotia and Howard Johnson’s, Truro, Nova Scotia.

Feb 2003
Medication Use in CHF – A review of the Evidence. Museum of Industry, Stellarton, Nova Scotia

Current Position
Clinical Pharmacy Specialist/Leader – Heart and Vascular Program/Research/DUE, Department of Pharmacy
St Michael’s Hospital
Assistant Professor
Leslie L Dan Faculty of Pharmacy
University of Toronto

Contact Info:
Department of Pharmacy
St Michael’s Hospital
30 Bond Street, Toronto, ON
M5B 1W8
Phone: (416) 864-5427
Fax: (416) 864-6058
E-mail: kertlandh@smh.toronto.on.ca

Past Position:
Director, Doctor of Pharmacy Programme
(March 08 - Rhodes University January 09)
Grahamstown, South Africa

Education:
Fellowship, Cardiovascular Therapeutics
Hartford Hospital
Hartford, Connecticut

Doctor of Pharmacy
Wayne State University
Detroit, Michigan

Pharmacy Practice Residency
McMaster University Medical Centre
Hamilton, Ontario

Bachelor of Science in Pharmacy
University of Toronto
Toronto, Ontario

Recent Publications:

Articles:

Yan AT, Yan RT, Tan M, Hackman DG, Leblanc KL, Kertland H, et al Contemporary Management of dyslipidemia in High Risk patients: Targets Still Not Met Am J Med 2006;119:676-83.

Fitchett DH, Borgundvaag B, Cantor W, Cohen E, Dhingra S, Fremes S, Gupta M, Hefferman M, Kertland H, Husain M, Langer A, Letovsky E, Goodman SG for the Renewal of the NonSTE ACS algorithm group Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm Can J Cardiol 2006;22

Kertland H. Keeping the Beat Pharmacy Practice September 2004

Kwok L, Kertland H Antiplatelet agents in Cardiovascular Disease Pharmacy Practice (CE Lesson) May 2004

Paradiso-Hardy F, Gordon W, Jackevicius C, Kertland H, Pearson F, Pickering J et al The Importance of In-Hospital Statin Therapy for Patients with Acute Coronary Syndromes Pharmacotherapy 2003:23:506-513.

Abstracts:

Njuguna CW, Kertland H, Parrish A. Drug Utilization Evaluation (DUE): Are we using warfarin in the safest manner? SAAHIP 2009

Munsamy JL, Parish A, Kertland H validation of a fixed-dose, weight adjusted, subcutaneous unfractionated heparin for acute treatment of venous thromboembolism SAAHIP 2009

Singh S, Kertland H Role of the pharmacist as a team leader for total parenteral nutrition in a south African tertiary hospital complex SAAHIP 2009

Brown TER, Chant C, Dresser L, Einarson T, Kertland H Comparison of student course evaluations between a Full-time and Part-time Doctor of Pharmacy Program AJPE 2008;72:61

Chant C, Dresser L, Kertland H, Brown TER Webcam utilization in a part-time Distance-Learning Doctor of Pharmacy Program AJPE 2008;72:81

Lail S, Jeffrey J, Bhojwani R, Fitchett D, Kertland H Root Cause Analysis for Major Bleeding in Patients with Acute Coronary Syndrome Pharmacotherapy 2008;

Research:

Barriers and Facilitators to obtaining an accurate Medication History – Coinvestigator MedBuy Endowment Fund $7500

Evaluation of Smoking Cessation Invertention Program Co-Investigator

The Accuracy of Patient Weights Used for the Dosing of Weight-Based Pharmacologic Agents in Acute Coronary Syndromes Co-investigator

Assessment of Pharmacist-delivered patient education at St Michael’s Hospital Principal investigator Funded by: Medbuy Endowment Fund $9,000

COMMITTEES/APPOINTMENTS

Reviewer - Canadian Journal of Hospital Pharmacy
CPhA - Editorial Review Panel e-Therapeutics 2005 -
Canadian Pharmacist’s Journal
Annals of Pharmacotherapy
Lancet
Pharmacotherapy

Canadian Cardiovascular Pharmacists Network
Member 1995 – present,
Chair 1998/99, 2006/07
Chair Elect 2005/06

AFFILIATIONS American College of Clinical Pharmacy
Association of Faculties of Pharmacy in Canada
Canadian College of Clinical Pharmacy
Canadian Cardiovascular Pharmacy Network
Canadian Cardiovascular Society
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists

Education:
Bachelor of Science in Pharmacy, University of Toronto
Hospital Pharmacy Residency, St. Michael’s Hospital, Toronto
Doctor of Pharmacy Degree, University of Colorado Health Sciences Centre, Denver CO

Kori Leblanc BScPhm, ACPR, PharmD
Clinical Services Building - BCS 077
585 University Avenue
Toronto, ON M5G 2N2
Tel: 416-340-4800 ext.8964
Fax : 416-340-3685
Email : kori.leblanc@uhn.on.ca

Current Position/Practice Site:
Associate Professor of Medicine
Co-Director, Cardiac Transplant Clinic
Co-Medical Director and Director of Research, Cardiovascular Risk Reduction Clinic
Division of Cardiology
Mazankowski Alberta Heart Institute
University of Alberta

Contact Information:
Suite 2C2 Walter C. Mackenzie Health Sciences Centre
8440 – 112th Street
Edmonton, Alberta
T6G 2B7

E-Mail: Glen.Pearson@ualberta.ca
Phone: (780)407-1590
Fax: (780)407-1496

Practice Expertise/Research Interests:
• Heart Transplantation/Immunotherapy
• Dyslipidemia
• Comprehensive CV Risk Reduction
• Cardiovascular Pharmacotherapy
• CV Health Outcomes Research
• General Cardiology

Selected Peer-Reviewed Publications:

1. Ostad N, Pearson GJ. Dual Antiplatelet Therapy for Cardiovascular Protection: Indication, Duration, and Other Considerations. Geriatrics & Aging 2009;12(4): 186-191.

2. Zuk DM, Pearson GJ. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients—a systematic review. Transplantation Reviews 2009;23:171-177.

3. Mansell H, Pearson GJ. Macrolide Antibiotics and Calcineurin Inhibitors: Avoiding a Far Too Common Drug Interaction in Transplant Patients. Canadian Pharmacist Journal (CPJ) 2009;142(2):68-70.

4. Pearson GJ. Gaps, Goals and Getting to Target: A Call to Action for Pharmacists! (Guest Editorial). Canadian Pharmacist Journal (CPJ) 2008;141(Supplement 2):S6.

5. Pearson GJ, Thompson AE, Semchuk W. 2007 Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease by Pharmacists. Canadian Pharmacist Journal (CPJ) 2008;141(Supplement 2):S11-S18.

6. Pearson GJ. Should Pharmacists Have Prescribing Privileges? The “Pro” Side. Can J Hosp Pharm 2008;61(5):351-2.

7. Pearson GJ, Olson KL, Panich NE, Tsuyuki RT, Majumdar S, Gilchrist DM, Damani A, Francis GA. Maintenance of Improved Lipid Levels Following Attendance at a Cardiovascular Risk Reduction Clinic – A 10-year experience. Vascular Health and Risk Management 2008;4(5):1127-1135.

8. Pearson GJ, Thompson AE, Semchuk W. 2007 Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease by Pharmacists. Canadian Pharmacist Journal (CPJ) 2007:140(6):383-88.

9. Pearson GJ. Evolution in the Practice of Pharmacy – Not a Revolution!. CMAJ 2007;176:1295-96.

10. Chan M, Pearson GJ. New Advances in Anti-Rejection Therapy. Current Opinion in Cardiology 2007;22:117-22.

11. Burton JR, I Burton, Pearson GJ. Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient. Ann Pharmacother 2007;41:133-37.

12. Pearson GJ, Francis GA, Romney JS, Gilchrist DM, Opgenorth A, Gyenes GT. Clinical Efficacy and Tolerability of Ezetimibe in High-Risk Patients Managed in a Specialty Cardiovascular Risk Reduction Clinic. Can J Cardiol 2006;22:939-45.

13. Meyer SR, Modry DL, Norris CM, Pearson GJ, Bentley MJ, Koshal A, Mullen JC, Rebeyka IM, Ross DB, Wang SH. Pre-Transplant Diabetes, Not Donor Age, Predicts Long-Term Outcomes in Cardiac Transplantation. J Card Surg 2006;21:117-124.

14. Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ. Supra-therapeutic response to ezetimibe concomitantly administered with cyclosporine. Ann Pharmacother 2005;39(9):1561-5.

15. Yamada C, Johnson JA, Robertson P, Pearson GJ, Tsuyuki RT. Long Term Impact of a Community Pharmacist Intervention on Cholesterol Levels in Patients at High Risk for Coronary Heart Disease Events: The Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus) Extended Follow-up. Pharmacotherapy 2005;25(1):110-115.

16. Strachan D, Burton I, Pearson GJ. Is Oral Azithromycin Effective for the Treatment of Cyclosporine-Induced Gingival Hyperplasia in Cardiac Transplant Recipients? Journal of Clinical Pharmacy and Therapeutics 2003;28(4):329-338.

17. Pharand C, Ackman ML, Jackevicius C, Paradiso-Hardy FL, Pearson GJ, for the Canadian Cardiovascular Pharmacists Network (CCPN/RCPC). Use of OTC and Herbal Products in Patients with Cardiovascular Disease. Ann Pharmacother 2003;37(6):899-904.

18. Paradiso-Hardy FL, Gordon WL, Jackevicius CA, Kertland HR, Pearson GJ, Pickering JL, Poirier L, Semchuk WM, Verret L. The Importance of In-Hospital Statin Therapy for Patients with Acute Coronary Syndromes. Pharmacotherapy 2003;23(4)506-513.

19. Taher TH, Dzavik V, Reteff EM, Pearson GJ, Woloschuk BL, Francis GA. Tolerability of statin-fibrate and statin-niacin combination therapy in dylipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002 Feb 15; 89(4):390-394.

20. Thompson AE, Hirsch GM, Pearson GJ. Assessment of New Onset Post-Coronary Artery Bypass Atrial Fibrillation: Current Practice Pattern Review and Development of Treatment Guidelines. J Clin Pharm Ther 2002;27(1):21-37.

21. Pearson GJ, Simmons WKT, Cooke CA, Sketris I. Evaluation of the Use of Evidence-Based Angiotensin-Converting Enzyme Inhibitor Criteria for the Treatment of Congestive Heart Failure: Opportunities for Pharmacists to Improve Patient Outcomes. J Clin Pharm Ther 2001;26(5):351-361.

Academic Background:
Fellowship in Cardiovascular Pharmacology
Hôpital du Sacré-Coeur de Montréal and Université de Montréal, Montréal, Québec
Fellowship in Cardiovascular Therapeutics
Hartford Hospital, Hartford, Connecticut and University of Connecticut, School of Pharmacy, Storrs, Connecticut
Doctor of Pharmacy (Pharm.D.)
Philadelphia College of Pharmacy and Science, Philadelphia, Pennsylvania
Bachelor of Pharmacy (B.Pharm.)
Université de Montréal, Montréal, Québec

Research experience and interest:
My research is divided into two programs in the area of coronary artery disease:
- Determinant of subendocardial ischemia in a porcine model.
- Evaluation of platelet reactivity and responsiveness to antiplatelet drugs in patients with coronary artery disease.

Articles recently published:

- Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-85. (IF 7.924)

- Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Diodati JG. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. Ther Drug Monit 2008;30:372-8. (IF 3.03)

- Lordkipanidzé M, Pharand C, Palisaitis DA, Turgeon J, Schampaert E, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8. (IF 7.34)

- Lordkipanidzé M, Pharand C, Palisaitis DA, Diodati JG. Aspirin resistance in cardiovascular disease. Pharmacol Therapeut 2006;112:733-43. (IF 8.36)

- de Chantal M, Diodati JG, Nasmith JB, Amyot R, LeBlanc AR, Schampaert E, Pharand C. Progressive epicardial coronary blood flow reduction fails to produce ST-segment depression at normal heart rate. Am J Physiol 2006;291:2889-96. (IF 3.56)

- Nguyen TA, Diodati J, Pharand C. Response to clopidogrel: is there a resistance phenomenon?. J Am Coll Cardiol 2005;45:1157-64.

Reginald E. Smith, Pharm.D. , ACPR
Clinical Specialist,
Cardiovascular Medicine & Thrombosis Clinic
Royal Jubilee Hospital & Victoria Heart Institute
Victoria, B.C

Reg Smith is a Clinical Specialist in Cardiovascular Medicine & Thrombosis at the Royal Jubilee Hospital (RJH) in Victoria, BC, and a Clinical Researcher at the Victoria Heart Institute.

Dr. Smith operates the thromboembolism clinic at the Royal Jubilee Hospital and oversees numerous clinic visits per year for venous and arterial thromboembolism. His cardiology practice includes a heart catheterization lab and a high volume electrophysiology lab.

He obtained his B.Sc.(Pharm) from U.B.C. and his hospital residency at Burnaby Hospital, then after working in Saudi Arabia completed his Pharm.D. at the University of Kentucky.

Dr. Smith has been a principle or co-investigator in numerous cardiovascular clinical trials. He is an active member of the Canadian Cardiovascular Society (CCS) and is also member of the Thrombosis Interest Group of Canada (TIGC).

Dr. Smith is an instructor in the Faculty of Medicine, Island Medical Program, University of Victoria and the Faculty of Pharmaceutical Sciences at the University of British Columbia. He is an Adjunct Associate Professor of Nursing at the University of Victoria.

Education:
Non-traditional PharmD, University of Colorado, in progress, 2006-present
Accredited Canadian Pharmacy Residency, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia
BScPharm, Dalhousie University, Halifax, Nova Scotia

Clinical practice:
Hypertension clinic, ambulatory care

Research/clinical interests:
Management of hypertension and dyslipidemia by pharmacists

Committees:
- Canadian Hypertension Education Committee, Implementation Task Force
- Chair-Elect (2008-2009), Banff Western Conference, Canadian Society of Hospital Pharmacists

Published Papers:

2008 Thompson A, Campbell NC, Cloutier L, Costello J, Dawes M, Hickey J, et al, for the Canadian Hypertension Education Implementation Task Force. Tackling the burden of hypertension in Canada: encouraging collaborative care. Canadian Family Physician 2008 Dec;54:1659-67.

2008 Chan AHW, Campbell NR, Lewanczuk RZ, Semchuk W, Thompson AE, Tsuyuki RT, for the Canadian Hypertension Education Implementation Task Force. The 2008 Canadian Hypertension Education Program Guidelines for the management of hypertension by pharmacists. Can Pharm J 2008 Nov/Dec;141:In press.

2007 Pearson GJ, Thompson AE, Semchuk W. 2007 guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. Can Pharm J 2007;140(6):383-8.

Recent Presentations:

2007-2009 Hypertension Lectures and Seminar, 2nd year Cardiology Module, Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, Edmonton, Alberta

2006-2008 Interpreting Laboratory Values: An Introductory Course for Pharmacists, Continuing Pharmacy Education offered cooperatively through the Alberta College of Pharmacists and the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, Edmonton, Alberta

Workshops:

Presentations include Electrolytes and Liver Function Tests, Hypertension and Cholesterol Tests (September 21/22, 2007; September 19/20, 2008) Distance learning session (Elluminate) facilitation: Lipid Case, November, 2006-08

2008 2008 Hypertension Update, The 3rd Annual Atlantic Canada Fall Symposium: Contemporary Therapeutic Issues in Cardiovascular Disease, October 18-19, 2008, Halifax, Nova Scotia

2008 Studies That Should Change Your Practice: HYVET and ENHANCE, The 8th Annual Contemporary Cardiovascular Therapy Fall Symposium, September 28, 2008, Regina, Saskatchewan

2008 Hypertension Workshop, September 5, 2008, Kananaskis, AB

2008 Update on Hypertension, The 11th Annual Contemporary Therapeutic Issues in Cardiology, Nephrology and Diabetes, April 26, 2008, Toronto, Ontario